Therapy-resistant and -sensitive lncRNAs, SNHG1 and UBL7-AS1 promote glioblastoma cell proliferation

The current treatment options for glioblastoma (GBM) can result in median survival of 15-16 months only, suggesting the existence of therapy-resistant factors. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play an essential role in the development of various brain tumors, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Mei, Ma, Rong, Li, Huaqing, Cui, Juan, Zhang, Chi, Zhao, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933655/
https://www.ncbi.nlm.nih.gov/pubmed/35313638
http://dx.doi.org/10.1155/2022/2623599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933655/
https://www.ncbi.nlm.nih.gov/pubmed/35313638
http://dx.doi.org/10.1155/2022/2623599

Ejemplares similares